SLGC Stock Overview
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$1.73 |
| Beta | 1.64 |
| 1 Month Change | -13.93% |
| 3 Month Change | 14.13% |
| 1 Year Change | -28.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S
Dec 19
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target
Nov 10SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable
Apr 17Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term
Apr 02SomaLogic appoints former Foundation Medicine chief as executive chair
Oct 17SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay
Jul 26We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely
Jun 06SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside
Apr 12Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)
Mar 09We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth
Dec 28SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics
Oct 14Shareholder Returns
| SLGC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -14.3% | -0.5% | -1.1% |
| 1Y | -28.1% | -5.9% | 22.4% |
Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -2.7% over the past year.
Return vs Market: SLGC underperformed the US Market which returned 21% over the past year.
Price Volatility
| SLGC volatility | |
|---|---|
| SLGC Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLGC's share price has been volatile over the past 3 months.
Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 451 | Adam Taich | www.somalogic.com |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.
Standard BioTools Inc. Fundamentals Summary
| SLGC fundamental statistics | |
|---|---|
| Market cap | US$396.23m |
| Earnings (TTM) | -US$130.38m |
| Revenue (TTM) | US$81.72m |
4.8x
P/S Ratio-3.0x
P/E RatioIs SLGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGC income statement (TTM) | |
|---|---|
| Revenue | US$81.72m |
| Cost of Revenue | US$97.89m |
| Gross Profit | -US$16.16m |
| Other Expenses | US$114.22m |
| Earnings | -US$130.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | -19.78% |
| Net Profit Margin | -159.54% |
| Debt/Equity Ratio | 0% |
How did SLGC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/09 06:27 |
| End of Day Share Price | 2024/01/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Brandon Couillard | Jefferies LLC |
| Daniel Brennan | TD Cowen |